Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Niagen Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Niagen Bioscience's regulatory disclosures and financial reporting.
Niagen Bioscience (Nasdaq:NAGE) filed a Form 8-K detailing the outcomes of its 24 June 2025 Annual Meeting.
- 2017 Equity Incentive Plan: share reserve increased by 4,750,000 shares.
- New ESPP: 650,000 shares available; purchase price set at 85% of the lower of the offering- or purchase-date close.
- All eight directors re-elected; Crowe LLP ratified as auditor.
- Advisory say-on-pay passed (54,899,483 for / 1,160,619 against).
The amended plan (Ex. 10.1) and ESPP (Ex. 10.2) were filed; no other material changes were disclosed.
Form 4 filing reveals that Wendy Wing Tak Yu, Director at Niagen Bioscience (NAGE), received a stock option grant on June 24, 2025. The derivative securities transaction details include:
- Granted 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- 100% vesting scheduled for June 24, 2026
- Options expire on June 23, 2035
The filing, submitted by attorney-in-fact Jeong James Lee on June 26, 2025, indicates a standard director compensation grant with a one-year cliff vesting schedule. This represents a new position in derivative securities for the director, with direct ownership of all 20,000 options.
Niagen Bioscience (NAGE) Director Kristin Patrick received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with the following terms:
- Exercise price set at $14.13 per share
- 100% vesting scheduled for June 24, 2026
- Options expire on June 23, 2035
- Total grant value will be determined by stock price appreciation above $14.13
The Form 4 filing was signed by Attorney-in-Fact Jeong James Lee on June 26, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a 10-year exercise window following the one-year cliff vesting period.
Steven D. Rubin, Director of Niagen Bioscience, was granted 20,000 stock options on June 24, 2025. The options have the following key terms:
- Exercise price set at $14.13 per share
- Vesting schedule: 100% vesting on June 24, 2026
- Expiration date: June 23, 2035
- Securities underlying the options: Common Stock
- Direct ownership form
The Form 4 filing was signed by James Lee as attorney-in-fact on June 25, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a one-year cliff vesting requirement.
Director Gary Ng Wang Yu of Niagen Bioscience (NAGE) was granted stock options on June 24, 2025. The key details of this Form 4 filing include:
- Received 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- Options will vest 100% on June 24, 2026
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule suggests a standard annual director equity award structure. The 10-year exercise period from the grant date provides long-term alignment with shareholder interests.
Form 4 filing reveals that Ann Cohen, Director at Niagen Bioscience, was granted stock options on June 24, 2025. Key details of the transaction:
- Received 20,000 stock options to purchase common stock
- Exercise price set at $14.13 per share
- Options will vest 100% on June 24, 2026
- Options expire on June 23, 2035
- Direct ownership form of securities
This grant represents a standard director compensation package, with a one-year cliff vesting schedule. The filing was signed by James Lee as attorney-in-fact on June 25, 2025. No other securities transactions were reported in this filing.
Form 4 filing reveals that Frank L. Jaksch Jr., Director of Niagen Bioscience (NAGE), was granted 20,000 stock options on June 24, 2025. The options have the following key terms:
- Exercise price set at $14.13 per share
- Options will vest fully (100%) on June 24, 2026
- Expiration date is June 23, 2035
- Underlying security is Common Stock
The transaction was reported through an attorney-in-fact, James Lee Jeong, and filed on June 25, 2025. This grant represents a new position in derivative securities for the director, with direct beneficial ownership of all 20,000 options. The filing indicates standard compensation practices for board members through equity-based incentives.
FAQ
What is the current stock price of Niagen Bioscience (NAGE)?
What is the market cap of Niagen Bioscience (NAGE)?
